biotech
Pertuzumab Boosts Survival in Recurrent Ovarian Cancer Patients
Filed in archive Drugs, Vaccines and Therapeutics by ruth on September 28, 2007
According to Phase II clinical trial data with 130 patients, an experimental drug called pertuzumab prolonged the survival time for women with stage 3 recurrent ovarian cancer. Pertuzumab Boosts Survival in Recurrent Ovarian Cancer Patients

Pertuzumab is a monoclonal antibody being developed by Genentech as a chemotherapeutic drug against prostate, breast, and ovarian cancers.
In the study, pertuzumab was administered in combination with a standard chemotherapy agent sometime after the initial treatments had been given, and after the re-emergence of cancer. Makhija said the new combination added weeks to the standard survival period for recurrent patients, and the drug combo was well-tolerated by the body and caused minimal side effects.

The results were presented in the recently concluded European Cancer Conference held in Barcelona, Spain. The Phase II study is now closed, and a larger Phase 3 study of pertuzumab set to include hundreds of U.S. women is being planned.

Permalink: Pertuzumab Boosts Survival in Recurrent Ovarian Cancer Patients
Tags: pertuzumab  cancer  genentech  ovarian+cancer  monoclonal+antibody  biotech  recurrent+ovarian  pertuzumab+ 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/94096
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Pertuzumab Boosts Survival in Recurrent Ovarian Cancer Patients:

  • Currently 5.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 5.00 out of 3 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!